Date: 2017-08-16
Type of
information: Clinical trial authorisation
phase: 2
Announcement: clinical trial authorization
Company: Medivir (Sweden)
Product: MIV-711
Action
mechanism:
- cathepsin inhibitor. MIV-711 is being developed as a DMOAD (Disease-Modifying Osteoarthritis Drug) , i.e. a drug to slow or reverse the progression of the degeneration of joints affected by osteoarthritis.
Disease: osteoarthritis
Therapeutic
area: Rheumatic diseases - Inflammatory diseases – Bone diseases
Country: USA
Trial
details:
Latest
news:
- • On August 16, 2017, Medivir announced that the Investigational New Drug (IND) application for MIV-711 has been accepted and the IND is now open with the FDA. The FDA acceptance enables clinical development of MIV-711 in the US, in addition to the already completed and ongoing studies in Europe.
Is
general: Yes
